Caixa Capital Risc launches a new fund in the Biotech sector

Integral service around a transaction
BY : Diego GutiérrezApril Wed, 2014
private equityCaixa Capital Riscthe "la Caixa" group's venture capital manager for innovative companies in the early stages, which had 4 investment vehicles specialising in Biotechnology, Industry and ICT, has launched a new Biotechnology fund together with the CDTI.


Experience in the biotechnology sector

La Caixa already had, Caixa Capital BioMedThe company, a private equity with a total committed capital of €23 million to invest in medical technology, new therapies, diagnostics and services. Since its creation in 2011, the vehicle has invested 14m in 13 companies, which have raised more than private investment national and international support for their business projects.

Transactions carried out

Among the companies that have received funding are STAT-DIAGNOSTICA which designs, develops, manufactures and markets a system that integrates molecular diagnostic and immunoassay tests in a device and cartridges. Together with Caixa Capital BioMed also participated in the series B round, which raised €17M.  Kurma Life Sciences Partners Ysios Capital, Axis,  Idinvest, Boehringer Ingelheim Venture Fund.

Another recent operation, carried out in February 2014, involves Genmedica Therapeutics. 

The Catalan biopharmaceutical company Genmedica Therapeutics has completed a financing round 1M to fund the development of a drug for the treatment of type 2 diabetes. The capital increase has been mainly covered by the company's own shareholders, including Caixa Capital Risc.

Caixa Invests Biomed

The new fund, Caixa Innvierte BioMed II, which has the support of the CDTI and will have an investment volume of €35M will enable Caixa Capital BioMed to complete its investment period and focus on the value creation of its investee companies.

"The creation of the new fund shows us the interest that Caixa Capital Risc , which sees an opportunity in the Biotechnology sector, and according to the latest report of the Spanish Association of Biocompanies (ASEBIO), Spain ranks ninth in the world and fifth at European level in scientific production, a sector that in 2013 accounted for 7.15% of Spain's GDP. In 2011, there were 3,025 companies related to biotechnology activities in the country. There is a strong culture of spin-off in the sector, with between 10 and 12 new companies being created every year from public institutions," says Diego Gutierrez, the group's expert in alternative finance. Abra Invest.

Other posts that may interest you

Latest investments in "disease diagnostics

 Since 2007, US private equity has invested 2400MM$ in the healthcare sector.

Healthcare does not feel the impact of the crisis

If you want to know more or if you think we can help you, do not hesitate to contact us.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?